Clinical observation of pyrrotinib maleate in the treatment of trastuzumab-resistant HER-2 positive advanced breast cancer

ObjectiveTo investigate the efficacy and adverse reaction of pyrrotinib maleate in the treatment of trastuzumab-resistant human epidermal growth factor receptor 2(HER-2) positive advanced breast cancer.

MethodsThe clinical data of 88 patients treated with pyrrotinib maleate were retrospectively analyzed.The objective response rate(ORR), disease control rate(DCR) clinical benefit rate(CBR), progress free survival(PFS), prognostic factor and adverse reaction in all cases were analyzed.

ResultsThe analysis results of short-term efficacy of patients showed that 1 case of complete response, 33 cases of partial response, 34 cases of stable disease and 20 cases of progression disease were identified, and the ORR, DCR, CBR and median PFS were 38.6%, 77.3%, 64.8% and 11.335 months, respectively.The results of rank sum test showed that the ECOG score was correlated with the short-term efficacy(P < 0.05).The Log-rank univariate analysis showed that the ECOG score and trastuzumab resistance affected the PFS.The adverse reactions included the diarrhea, nausea and vomiting, fatigue, hand-foot syndrome and oral ulcer symptoms.

ConclusionsThe oral pyrroitini-based regimens can be effectively used in trastuzumab resistant patients with advanced, relapsing and metastatic HER-2 positive breast cancer, and the adverse reactions can be tolerated.